Isocitrate dehydrogenase (IDH) was used as a pivotal molecular parameter for glioma reclassification [31, 35], besides being a significant prognostic biomarker and potential therapeutic target for glioma patients [36]. This evidence concerns the gene IDH2 and central nervous system cancer.